Format

Send to

Choose Destination
Thyroid. 2010 Jun;20(6):647-51. doi: 10.1089/thy.2009.0466.

Salivary gland malignancy and radioiodine therapy for thyroid cancer.

Author information

1
Department of Medicine, Washington Hospital Center, Washington, DC 20010-2910, USA.

Abstract

BACKGROUND:

The risk of second primary malignancies in patients with well-differentiated thyroid cancer is of special interest because of the common use of radioactive iodine (RAI) ablation and/or treatment of these patients and the theoretical risk of subsequent nonthyroid malignancies associated with the radiation exposure. This brief report focuses specifically on the occurrence of second primary malignancies of the salivary glands. RAI residency within salivary tissues is known to have both acute and chronic consequences on salivary function, but secondary neoplasia is quite unusual.

SUMMARY:

We present a very rare case of a patient with papillary thyroid cancer treated with 600 mCi of RAI, who subsequently developed salivary gland cancer.

CONCLUSIONS:

We recommend salivary gland protection to diminish potential side effects after the exposure to radioiodine. On the basis of our experience we suggest administration of sialogogues (such as lemon juice) continuously, every 30-60 minutes for 24 hours, after RAI administration.

PMID:
20470209
DOI:
10.1089/thy.2009.0466
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center